Home > About EXJADE > Efficacy

Once-daily EXJADE® Provides Total Body Iron Chelation Across Anemias

EXJADE removes iron from the heart and the liver and demonstrates efficacy across clinical parameters.

Learn more about how EXJADE reduces toxic iron in patients with:

EXJADE reduces serum ferritin across anemias 1, 2

Click on the serum ferritin arrows to see reductions in liver iron concentration in the same patient type.

For information on efficacy in non-transfusion-dependent thalassemia, see the link above.

Serum Ferritin Levels Across Anemias

IRON TOXICITY ACROSS UNDERLYING ANEMIAS

Iron toxicity increases morbidity and mortality across a range of patients.

Learn more

SAFETY PROFILE ACROSS ANEMIAS

Learn more

References

  1. Data on file. Novartis Pharma AG, Basel, Switzerland.
  2. Gattermann N, Finelli C, Della Porta M, et al. Deferasirox in iron overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large1-year EPIC study. Leuk Res. 2010;34(9):1143-1150.
  3. Lee JW, Yoon SS, Shen ZX, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. 2010;116(14):2448-2454.
  4. Kwiatkowski JL, Kim HY, Thompson AA, et al. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood. 2012;119(12):2746-2753.
  5. Greenberg PL, Koller CA, Cabantchik ZI, et al. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res. 2010;34(12):1560-1565.
  6. Greenberg PL, Koller CA, Glynos T, Paley C, Schiffer CA. Change in liver iron concentration, serum ferritin and labile plasma iron over 1 year of deferasirox (EXJADE®) therapy in a cohort of patients with MDS. Poster presented at 10th International Symposium on Myelodysplastic Syndromes. [P104] Leuk Res. 2009;33 (suppl 1):S120.
  7. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508.
  8. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.